5 to 6, 2015 Arrowhead's 7th Annual Personalized & Precision Medicine Conference is coming to Baltimore, On October 5-6 MD, 2015 as an official satellite television event to the American Society for Human Genetics Annual Conference. This Meeting will be an exciting opportunity to deliberate alongside several stakeholders and professionals regarding the ways that healthcare has been reshaped by personalized and precision medicine. This conference brings together multiple stakeholders, including payers, molecular diagnostics businesses, genome analysis/interpretation companies, clinicians and many others in order to provide attendees with a holistic view of the precision medication landscape.Pipeline Highlights ANAVEX’s SIGMACEPTOR-N plan pipeline is targeted on developing disease-modifying treatments for neurological conditions. Considerable advancements have been made with ANAVEX 1-41. In recent pre-clinical animal research, the compound demonstrated significant neuroprotective benefits through the prevention of oxidative stress, which damages and destroys cells and can be thought to be a major reason behind Alzheimer’s disease. The novel mechanism of actions of ANAVEX 1-41 demonstrates that the compound may influence the course of Alzheimer’s disease and prevent or limit the creation of plaques that eliminate human brain cells in the hippocampus, the proper part of the human brain that regulates learning, emotion and memory.